RESUMO
OBJECTIVE: To compare the efficacy of the CAMS-2005 and CAMS-2009 regimens in treating children with non-core binding factor acute myeloid leukemia (non-CBF AML) and to study the prognosis factors. METHODS: A total of 161 children who were initially diagnosed with non-CBF AML from April 2005 to December 2015 were enrolled as study subjects, and were divided into a CAMS-2005 regimen group (n=52) and a CAMS-2009 regimen group (n=109) according to the chemotherapy regimen provided. The efficacy was retrospectively compared between the two groups. RESULTS: The complete remission (CR) rate at the first course of treatment was higher in the CAMS-2009 regimen group than that in the CMAS-2005 regimen group (63.3% vs 46.2%; P<0.05). There were no significant differences between the two groups in treatment-related mortality rate (11.9% vs 17.3%), recurrence rate (27.5% vs 28.8%), and three-year overall survival (OS) rate (44%±5% vs 28%±6%) (P>0.05). Children who achieved CR at the first course of treatment had significantly higher OS and event-free survival rates than those who did not achieved CR (P<0.01). CONCLUSIONS: The CAMS-2009 regimen is superior to the CAMS-2005 regimen in improving the CR rate in children with non-CBF AML after induction treatment. Whether CR is achieved at the first course of treatment can affect the OS rate of children with non-CBF AML.
Assuntos
Leucemia Mieloide Aguda , Protocolos de Quimioterapia Combinada Antineoplásica , Criança , Humanos , Prognóstico , Indução de Remissão , Estudos RetrospectivosRESUMO
OBJECTIVE: To study the clinical features of Wiskott-Aldrich syndrome (WAS) in children. METHODS: A retrospective analysis was performed for the clinical data of 13 children with WAS. RESULTS: All 13 children were boys, with a median age of onset of 3 months (range 1-48 months) and a median age of 24 months (range 1-60 months) at the time of diagnosis. Of the 13 children, only 3 had typical WAS and the remaining 10 children had X-linked thrombocytopenia (XLT). The mean WAS score was 2 (range 1-3), the mean platelet count was 20.5×109/L [range (13-46)×109/L], and the mean platelet volume was 8.1 fl (range 6.7-12.1 fl). Lymphocyte subsets and immunoglobulins were measured for 4 children, among whom 1 (25%) had a reduction in both the percentage of CD3+T cells per lymphocyte and lymphocyte per nuclear cells, 1(25%) had a reduction in CD3-CD56+ NK cells. Among these 4 children, 1 (25%) had an increase in IgG, 2 (50%) had a reduction in IgM, 1 (25%) had a reduction in IgA, and 4 (100%) had an increase in IgE. A total of 14 gene mutations belonging to 13 types were found in 13 children, among which there were 9 missense mutations (65%), 2 splicing mutations (14%), 2 nonsense mutation (14%), and 1 frameshift mutation (7%). The median follow-up time was 39 months (range 3-62 months), and all 13 children survived. CONCLUSIONS: Children with WAS often have a young age of onset, and most of them are boys. Major clinical features include thrombocytopenia with a reduction in platelet volume. Missense mutation is the main type of gene mutation.
Assuntos
Trombocitopenia , Síndrome de Wiskott-Aldrich , Pré-Escolar , Humanos , Lactente , Masculino , Mutação , Estudos Retrospectivos , Proteína da Síndrome de Wiskott-AldrichRESUMO
Juvenile myelomonocytic leukemia (JMML) is a rare chronic myeloid leukemia in children and has the features of both myelodysplastic syndrome and myeloproliferative neoplasm. It is highly malignant and has a poor treatment outcome. Children with JMML have a poor response to conventional chemotherapy. At present, hematopoietic stem cell transplantation is the only possible cure for this disease. In recent years, significant progress has been made in targeted therapy for mutant genes in the Ras signaling pathway and demethylation treatment of aberrant methylation of polygenic CpG islands. This article reviews the treatment and efficacy evaluation of JMML.
Assuntos
Transplante de Células-Tronco Hematopoéticas , Leucemia Mielomonocítica Juvenil , Síndromes Mielodisplásicas , Criança , Humanos , Metilação , Transdução de SinaisRESUMO
OBJECTIVE: To analyze the clinical characteristics and factors affecting prognosis in children with severe aplastic anemia (SAA). METHODS: Two hundred and five children with SAA treated in our department from January 2008 to April 2018 were selected, and the clinical characteristics and factors affecting prognosis were retrospectively analyzed. RESULTS: Among 205 SAA children, the effective rate (CR+PR) at 3, 6 and 12 months after immunosuppressive therapy (IST) treatment was 50.9%, 59.0% and 73.9%, respectively, and 5-year overall survival rate was 93.1%±2.0%. Univariate analysis showed that 5-year overall survival rate of SAA children of spontaneous delivery was higher than that of cesarean section (P=0.039), while multivariate analysis showed that birth way had no significant influence on 5-year overall survival rate (P>0.05). The response rate at 3 months after IST of children with a recent history of decoration before SAA onset was higher than those without history of decoration (P<0.05). CONCLUSION: Most of the SAA children can achieve high response rate and overall survival rate. Patients with recent history of home/school decoration may be the factor affecting hematological response after 3 months of IST, but have no influence on long-term overall survival.
Assuntos
Anemia Aplástica , Cesárea , Criança , Feminino , Humanos , Imunossupressores , Gravidez , Prognóstico , Estudos Retrospectivos , Resultado do TratamentoRESUMO
OBJECTIVE: To understand the epidemiological characteristics of childhood acute lymphoblastic leukemia (ALL) by analyzing the clinical data of 982 patients. METHODS: A retrospective analysis was performed on 982 children with ALL who were admitted to our center from April 2008 to May 2015. The sex, age and season of onset, risk factors related with the disease, and molecular biological characteristics were analyzed. RESULTS: The ratio of male to female in ALL was 1.5â¶1, the median age of onset was 5 years old, and the peak age of onset was 2 to 5 years old. The peak season of onset was spring. Analysis of birth and feeding history showed that the children born after normal period of gestation accounted for 98.0%. Among the born children 55.9% of children were born with natural lobour, and 44.1% of children were born by cesarean section. The breast feeding children accounted for 79.8%, while artificial/mixed feeding children accounted for 20.2%. The median birth weight was 3.5 kg (1.8-7.2 kg). There were 34 cases (3.5%) with abnormal birth history, including 10 cases with umbilical cord around the neck. 31.4% of the patients had a recent history of house decoration, and the median exposure time to decoration environment was 12 months (1-36 months). Among the first to third grade relatives of the children, 44 patients (4.5%) sufferd from blood system diseases, including 23 patients with leukemia, 53 (5.4%) had malignant tumors, and most of them were lung cancer, digestive system tumors and breast cancer. The immunophenotype showed that B-ALL accounted for 90.7% and T-ALL accounted for 9.3%. In molecular biological tests, TEL/AML1 positive patients accounted for 21.0%, E2A/PBX1 positive patients accounted for 5.2%, BCR-ABL positive patients accounted for 6.1%, and MLL positive patients accounted for 2.5%. CONCLUSION: The childhood ALL occurs in more boys, the peak age of onset is 2-5 years old, the peak season of onset is spring, the peak of birth season is autumn and winter, the proportion of cesarean section, high birth weight and non-breastfeeding after birth are higher than the average value of infants in most parts of the country during the same period. The proportion of childhood ALL patient's exposure to ionizing radiation and house decoration environment, and relatives with history of blood and malignant tumors are high.
Assuntos
Cesárea , Leucemia-Linfoma Linfoblástico de Células Precursoras , Pré-Escolar , Feminino , Proteínas de Fusão bcr-abl , Humanos , Imunofenotipagem , Lactente , Masculino , Proteínas de Fusão Oncogênica , Leucemia-Linfoma Linfoblástico de Células Precursoras/epidemiologia , Gravidez , Estudos RetrospectivosRESUMO
BACKGROUND: Osteoarthritis (OA) is a prevalent chronic diseases characterized by formation of osteophytes and degradation of articular cartilage. Previous evidence has identified the regulatory effects of microRNAs (miRNAs) in OA. The goal of this study is to clearly explore the biological function of miR-1207-5p in OA. METHODS: MiR-1207-5p and C-X3-C motif chemokine receptor 1 (CX3CR1) expression in OA cartilages were revealed by accessing to Gene Expression Omnibus database. In vitro OA model was established by lipopolysaccharide (LPS) stimulation. Western blot and quantitative real-time polymerase chain reaction were conducted to detect the expression level of genes. Cell counting kit-8 (CCK-8) and flow cytometric experiments were performed to investigate the proliferation and apoptosis capacities of CHON-001 cells. Bioinformatics analysis was applied to predict the binding site of miR-1207-5p and CX3CR1, the connections of which were ascertained using luciferase reporter assay. RESULTS: MiR-1207-5p expression was decreased while CX3CR1 was increased in OA cartilages. Up-regulation of miR-1207-5p alleviated the LPS-induced damage in the view of cell proliferation, apoptosis and extracellular matrix (ECM) degradation. A target of miR-1207-5p CX3CR1, its down-regulation intensified the impacts of miR-1207-5p mimic, promoted proliferation and mitigated apoptosis. LPS exposure increased the protein expression of the phosphorylated IκBα and P65, and this phenomena was reversed due to miR-1207-5p up-regulation and CX3CR1 knockdown. The treatment of Betulinic acid (BA; an activator of nuclear factor-κB pathway) reversed the miR-1207-5p mimic-induced inhibitory effect on apoptosis in LPS-treated CHON-001. CONCLUSION: Our results highlight that miR-1207-5p can prevent CHON-001 from LPS-stimulated injury, providing a novel biomarker for OA progression and further advancing treatment of OA.